Expert opinion on pharmacotherapy

Using real-world data to assess semaglutide's impact on kidney disease risk in type 2 diabetes patients

Updated

Abstract

Semaglutide treatment was associated with a 26% reduction in the risk of major kidney disease events compared to a control group.

  • The control group included 896,257 individuals, while the semaglutide cohort consisted of 1,766 patients.
  • After adjusting for age, sex, socioeconomic status, and comorbidities, semaglutide treatment resulted in 702 kidney disease events, compared to 1,068 in the control group.
  • The hazard ratio for the primary event risk was 0.74, indicating a significant reduction in risk.
  • These findings align with a 24% risk reduction reported in the FLOW clinical trial.
  • Real-world evidence supports the renoprotective effects of semaglutide in managing renal complications.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free